Determination of MIC and disk diffusion quality control guidelines for meropenem–vaborbactam, a novel carbapenem/boronic acid β-lactamase inhibitor combination

Diagnostic Microbiology and Infectious Disease

Volumn 90, Issue 4, 2018, Pages 324-328

  Munson, Erik ^a   Huband, Michael D ^b   Castanheira, Mariana ^b   Fedler, Kelley A ^b   Flamm, Robert K ^b  

^a MARQUETTE UNIVERSITY   (United States)

^b JMI LABORATORIES   (United States)

Author keywords

CLSI M23; Meropenem vaborbactam; Quality control; RPX7009; VABOMERE

Indexed keywords

BACTERIAL ENZYME; CARBAPENEMASE; MEROPENEM PLUS VABORBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; MEROPENEM; THIENAMYCIN DERIVATIVE; VABORBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DISK DIFFUSION; FOOD AND DRUG ADMINISTRATION; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; URINARY TRACT INFECTION; DRUG EFFECT; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; PROCEDURES; STANDARDS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; BORONIC ACIDS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PRACTICE GUIDELINES AS TOPIC; QUALITY CONTROL; THIENAMYCINS;

EID: 85038811637     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2017.11.019     Document Type: Article

References (16)

1. Castanheira, M., Rhomberg, P.R., Flamm, R.K., Jones, R.N., Effect of the beta-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 60 (2016), 5454–5458.
2. CDC, Antibiotic resistance threats in the United States. 2013, Centers for Disease Control and Prevention, Atlanta, GA.
3. ClincalTrials.gov, Efficacy, safety, tolerability of carbavance compared to piperacillin/tazobactam in complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP), in adults. 2016, Rempex Pharmaecuticals, Bethesda, MD USA.
4. ClincalTrials.gov, Efficacy, safety, tolerability of carbavance compared to best available therapy in serious infections due to carbapenem resistant Enterobacteriaceae, in adults. 2017, Rempex Pharmaceuticals, Bethesda, MD USA.
5. CLSI, M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 4th ed., 2015, Clinical and Laboratory Standards Institute, Wayne, PA.
6. CLSI, M23-A4. Development of in vitro susceptibility testing criteria and quality control parameters, 4th ed., 2016, Clinical and Laboratory Standards Institute, Wayne, PA.
7. CLSI, M100-S27. Performance standards for antimicrobial susceptibility testing: 27th informational supplement, 2017, Clinical and Laboratory Standards Institute, Wayne, PA.
8. van Duijn, P.J., Dautzenberg, M.J., Oostdijk, E.A., Recent trends in antibiotic resistance in European ICUs. Curr Opin Crit Care 17 (2011), 658–665.
9. Griffith, D.C., Loutit, J.S., Morgan, E.E., Durso, S., Dudley, M.N., Phase 1 study of the safety, tolerability, and pharmacokinetics of the beta-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects. Antimicrob Agents Chemother 60 (2016), 6326–6332.
10. Hecker, S.J., Reddy, K.R., Totrov, M., Hirst, G.C., Lomovskaya, O., Griffith, D.C., et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58 (2015), 3682–3692.
11. Sievert, D.M., Ricks, P., Edwards, J.R., Schneider, A., Patel, J., Srinivasan, A., et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010. Infect Control Hosp Epidemiol 34 (2013), 1–14.
12. Thaden, J.T., Pogue, J.M., Kaye, K.S., Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae. Virulence 8 (2017), 403–416.
13. Turnidge, J., Bordash, G., Statistical methods for establishing quality control ranges for antibacterial agents in clinical and laboratory standards institute susceptibility testing. Antimicrob Agents Chemother 51 (2007), 2483–2488.
14. Tzouvelekis, L.S., Markogiannakis, A., Psichogiou, M., Tassios, P.T., Daikos, G.L., Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25 (2012), 682–707.
15. VABOMERE™ package insert. Available at http://www.vabomere.com/media/pdf/vabomere-us-prescribing-information.pdf, 2017.
16. Wenzler, E., Gotfried, M.H., Loutit, J.S., Durso, S., Griffith, D.C., Dudley, M.N., et al. Meropenem-RPX7009 concentrations in plasma, epithelial lining fluid, and alveolar macrophages of healthy adult subjects. Antimicrob Agents Chemother 59 (2015), 7232–7239.